Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
09 mai 2022 06h30 HE
|
Beam Therapeutics
BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait...
Beam Therapeutics to Participate in Upcoming May Investor Conferences
04 mai 2022 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting
02 mai 2022 16h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
25 mars 2022 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 25, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the Barclays 2022 Global Healthcare Conference
08 mars 2022 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 06h30 HE
|
Beam Therapeutics
Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned...
Beam Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
09 févr. 2022 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
10 janv. 2022 06h00 HE
|
Beam Therapeutics
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with...
Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones
09 janv. 2022 09h00 HE
|
Beam Therapeutics
First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for...
Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...